Serum Albumin, E.g., Bsa, Hsa, Etc. Patents (Class 530/363)
  • Publication number: 20120269828
    Abstract: The present invention relates to anti-drug vaccines based on conjugates between the drug and a non-immunogenic carrier protein. In preferred embodiments, it provides for anti-cocaine vaccines and their use to diminish the effects and/or use of cocaine in a subject.
    Type: Application
    Filed: April 20, 2012
    Publication date: October 25, 2012
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Shi-Xian Deng, Donald W. Landry, Gavreel Kalantarov, Trakht IIya
  • Publication number: 20120264158
    Abstract: Anionic acid-labile surfactants may generally comprise compounds represented by the formula: wherein R1 is independently selected from —(CH2)0-9CH3, R2 is selected from the group consisting of —H and —(CH2)0-5CH3, Y is an anion, X is a cation, and n is an integer from 1 to 8. Methods of making and using the anionic acid-labile surfactants are also described. The anionic acid-labile surfactants may be used to facilitate the solubilization of proteins and other molecules in an aqueous environment.
    Type: Application
    Filed: June 25, 2012
    Publication date: October 18, 2012
    Applicant: Protea Biosciences, Inc.
    Inventors: Matthew Jacob Powell, Trust Tariro Razunguzwa, George Augustine O'Doherty, Miaosheng Li
  • Publication number: 20120263739
    Abstract: The invention relates to anti-integrin antibodies which are covalently linked to nanoparticles, wherein these nanoparticles were prior loaded with chemotherapeutic/cytotoxic agents. The antibody-chemotherapeutic agent-nanoparticle conjugates according to the invention, especially wherein the antibody is MAb DI17E6 and the cytotoxic agent is doxorubicin show a significant increase of tumor cell toxicity.
    Type: Application
    Filed: October 21, 2010
    Publication date: October 18, 2012
    Applicant: MERCK PATENT GMBH
    Inventors: Klaus Langer, Marion Anhorn, Joerg Kreuter, Florian Rothweiler, Hagen von Briesen, Sylvia Wagner, Martin Michaelis, Jindrich Cinatl
  • Publication number: 20120264157
    Abstract: Anionic acid-labile surfactants may generally comprise compounds represented by the formula: wherein R1 is independently selected from —(CH2)0-9CH3, R2 is selected from the group consisting of —H and —(CH2)0-5CH3, Y is an anion, X is a cation, and n is an integer from 1 to 8. Methods of making and using the anionic acid-labile surfactants are also described. The anionic acid-labile surfactants may be used to facilitate the solubilization of proteins and other molecules in an aqueous environment.
    Type: Application
    Filed: June 25, 2012
    Publication date: October 18, 2012
    Applicant: Protea Biosciences, Inc.
    Inventors: Matthew Jacob Powell, Trust Tariro Razunguzwa, George Augustine O'Doherty, Miaosheng Li
  • Publication number: 20120258071
    Abstract: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.
    Type: Application
    Filed: April 13, 2012
    Publication date: October 11, 2012
    Inventors: Dirk Behrens, Elizabeth Bosch, Stephen K. Doberstein, Robert Forgan Halenbeck, Kevin Hestir, Min Mei Huang, Ernestine Lee, Haishan Lin, Thomas Linnemann, Shannon Marshall, Justin G. P. Wong, Ge Wu, Aileen Zhou, Cindy Leo, Lewis T. Williams
  • Publication number: 20120258077
    Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.
    Type: Application
    Filed: June 14, 2012
    Publication date: October 11, 2012
    Applicant: Theraclone Sciences, Inc.
    Inventors: Matthew Moyle, Jennifer Mitcham
  • Publication number: 20120244577
    Abstract: Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.
    Type: Application
    Filed: March 2, 2012
    Publication date: September 27, 2012
    Applicant: Zymeworks Inc.
    Inventors: Surjit Bhimarao Dixit, Igor Edmundo Paolo D'Angelo, David Kai Yuen Poon
  • Publication number: 20120244163
    Abstract: Disclosed are bispecific binding agents that specifically target both of the IGF-1 and the ErbB intracellular signaling pathways. For example, bispecific binding agents that comprise an anti-IGF-1R antibody and an anti-ErbB3 antibody connected by a linker are described herein. These bispecific agents are capable of antagonizing signal transduction by both of the IGF-1 and the ErbB signaling pathways and are useful in inhibiting the proliferation of tumor cells whose growth involves the signaling activity of both pathways.
    Type: Application
    Filed: April 10, 2012
    Publication date: September 27, 2012
    Applicants: DYAX CORP., MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Birgit SCHOEBERL, Ulrik NIELSEN, Arthur J. KUDLA, Arumugam MURUGANANDAM, David BUCKLER, Alexey Alexandrovich LUGOVSKOY, Jonathan Basil FITZGERALD, Lihui XU, Neeraj KOHLI
  • Publication number: 20120244634
    Abstract: The present invention provides a method for detection of a basic peptide by mixing a sample suspected to contain the basic peptide and a reagent containing denatured albumin and detecting turbidness due to a complex of the basic peptide and denatured albumin.
    Type: Application
    Filed: June 7, 2012
    Publication date: September 27, 2012
    Applicants: KAGOSHIMA UNIVERSITY, SYSMEX CORPORATION
    Inventors: Hiroyuki KABATA, Hideki TAKAHASHI, Ikuro MARUYAMA, Rena TSURUOKA
  • Publication number: 20120237998
    Abstract: We describe methods that allow either carbodiimides or other carboxyl-reactive substances to be mixed with solutions of carboxylic acids or phosphates or amines or combinations thereof, so as to form a homogeneous mixture which is then dried, preferably in a freeze drying process. The mixture is then contacted with an entity, which preferably involves the dissolution of the mixture with a buffered solution of the entity, so as to initiate a conjugation reaction between the entity and a component in the mixture.
    Type: Application
    Filed: March 15, 2011
    Publication date: September 20, 2012
    Applicant: INNOVA BIOSCIENCES LIMITED
    Inventors: Nicholas Gee, Annamaria Draghi
  • Publication number: 20120225087
    Abstract: The present invention provides novel nicotine hapten compounds and nicotine immunoconjugates which can be used for in vivo production of antibodies that specifically bind to nicotine. The invention also provides methods of using vaccines comprising the nicotine immunoconjugates in active or passive immunization protocols. The compositions and methods of the invention are useful for prevention and treatment of nicotine addiction.
    Type: Application
    Filed: September 14, 2010
    Publication date: September 6, 2012
    Applicant: The Scripps Research Institute
    Inventor: Kim D. Janda
  • Publication number: 20120219972
    Abstract: The present invention provides an isolated Ehrlichia peptide and therapeutic and diagnostic uses therefor.
    Type: Application
    Filed: January 31, 2012
    Publication date: August 30, 2012
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Sunil Thomas, David H. Walker
  • Publication number: 20120220489
    Abstract: The present invention provides a calibration reagent comprising a peptide conjugated to a protein carrier via a linker, wherein said peptide comprises an epitope of interest and the use thereof.
    Type: Application
    Filed: November 12, 2010
    Publication date: August 30, 2012
    Inventors: Maziar Assadi Gehr, Everson Nogoceke
  • Patent number: 8252747
    Abstract: A tissue adhesive sealant includes a cross-linkable protein in a solution that when combined with a cross-linking agent solution including an aldehyde and amino acid containing species reactive with the aldehyde cross-links to form a seal. The sealant is well suited for bonding tissue alone or in combination with a patch. The ratio between the aldehyde and the amino acid containing species is between 20:1 and 1:1 on an aldehyde moiety:amino acid or peptide subunit molar basis. Particularly strong seals are formed when the protein and cross-linking agent are present in a molar ratio of between 15:1 and 1:1.
    Type: Grant
    Filed: July 27, 2009
    Date of Patent: August 28, 2012
    Inventors: Johan Lowinger, Bruno Lowinger, Frank DeLustro, David Cox, David A. Browdie
  • Publication number: 20120213782
    Abstract: In certain aspects, the present invention provides BMP10 propeptides for use in treating a variety of disorders including heart disorders and other disorders associated with unwanted activity of the mature BMP10 polypeptide. The present invention also provides methods of screening compounds that modulate activity of BMP10.
    Type: Application
    Filed: April 9, 2012
    Publication date: August 23, 2012
    Applicant: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, John Knopf
  • Publication number: 20120208213
    Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.
    Type: Application
    Filed: December 20, 2011
    Publication date: August 16, 2012
    Applicant: RANDOX LABORATORIES LIMITED
    Inventors: Elouard Benchikh, Stephen Peter Fitzgerald, Paul John Innocenzi, Philip Andrew Lowry, Ivan Robert McConnell
  • Publication number: 20120208294
    Abstract: The invention relates to novel immunogens, antibodies, methods and kits for use in immunoassays to detect and quantify zaleplon, metabolites of zaleplon and indiplon. These are the first described immunoassays for these compounds and have greater sensitivity than alternative analytical techniques.
    Type: Application
    Filed: July 16, 2010
    Publication date: August 16, 2012
    Applicant: RANDOX LABORATORIES LTD.
    Inventors: Elouard Benchikh, Stephen Peter Fitzgerald, Philip Andrew Lowry, Ivan Robert Mcconnell
  • Publication number: 20120183549
    Abstract: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.
    Type: Application
    Filed: November 7, 2011
    Publication date: July 19, 2012
    Applicant: NOVARTIS AG
    Inventors: Michelle BRADLEY, Zarin BROWN, Steven John CHARLTON, Karen CROMIE, Bruno DOMBRECHT, Soren STEFFENSEN, Gino VAN HEEKE
  • Publication number: 20120171747
    Abstract: The present invention relates to microspheres comprising protein signal precursor molecules, or a carrier protein bonded to signal precursor molecules, wherein said signal precursor molecules are activatable to generate a detectable signal whilst remaining bonded to the carrier protein. Also disclosed is a method of making such microspheres comprising the steps of mixing protein molecules with a matrix former in solution; adding a reducing reagent to the mixture; removing the reducing reagent; and removing the matrix former to leave microspheres of protein molecules. Also disclosed are bioassay methods using the microspheres to provide signal amplification, including an amplification cycling procedure.
    Type: Application
    Filed: June 10, 2010
    Publication date: July 5, 2012
    Applicant: Supernova Diagnostics, Inc.
    Inventors: Wing Cheung Mak, Ling Wai Wong, Pui YeeCangel Chan, Reinhard Renneberg
  • Publication number: 20120164145
    Abstract: Helicobacter pylori, one of the most common human pathogens, is associated with the development of human chronic gastritis, peptic ulcers and gastric cancer. The invention relates to a ?1,6-glucan-containing Helicobacter pylori compound comprising the structure of Formula (I): wherein R is a ?-DDHep-3-?-L-Fuc-3-?-GlcNAc trisaccharide substituted with an ?1,6-glucan linked to an ?1,3-DD-heptan, and wherein the last DD-Hep residue of ?1,3-DD-heptan is capped with ?-GlcNAc residue. Compositions comprising the compound, uses of the compound, and antibodies raised against the compound are also described.
    Type: Application
    Filed: July 30, 2010
    Publication date: June 28, 2012
    Inventors: Eleanora Altman, Blair A. Harrison, Vandana Chandan
  • Publication number: 20120164146
    Abstract: An isolated peptide of 12-20 amino acids in length comprising the amino acid sequence SEQ ID NO:1, wherein the serine residue (S) at position 8 of SEQ ID NO:1 is phosphorylated, is provided. Also provided is a human monophosphorylated alpha-enolase isoform wherein the serine residue (S) at position 419 of the human alpha-enolase amino acid sequence (SEQ ID NO:2) is phosphorylated and in which other post-translational modifications may be present. Further provided are antibodies capable of specifically binding the peptide and/or the isoform of the invention. The peptide, the isoform and the antibodies of the invention may be used in the diagnosis and/or amelioration and/or treatment of pancreatic adenocarcinoma.
    Type: Application
    Filed: September 9, 2010
    Publication date: June 28, 2012
    Applicants: NATIMAB THERAPEUTICS S.R.L.
    Inventors: Francesco Novelli, Barbara Tomaino, Paola Cappello
  • Publication number: 20120156235
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Application
    Filed: December 23, 2009
    Publication date: June 21, 2012
    Applicant: MEDIMMUNE, LLC.
    Inventors: Josephine McAuliffe, Frances Palmer-Hill, Qing Zhu, Joann Suzich
  • Publication number: 20120141590
    Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.
    Type: Application
    Filed: September 30, 2011
    Publication date: June 7, 2012
    Inventors: Michael Malakhov, Fang Fang
  • Publication number: 20120135912
    Abstract: The invention provides novel 2D-VCAM-1 variant polypeptides and conjugates thereof that bind human VLA4. The invention also provides related polynucleotides, compositions, vectors, host cells, and methods.
    Type: Application
    Filed: May 10, 2011
    Publication date: May 31, 2012
    Applicant: PERSEID THERAPEUTICS LLC
    Inventors: MADAN M. PAIDHUNGAT, AMULYA NANISETTI, THOMAS BOUQUIN, KIM VILBOUR ANDERSEN, STEVEN J. CHAPIN, CLAUS KREBBER, RONG A. FAN, DANIEL MALASHOCK, AMY BRIDEAU-ANDERSEN, ERIK KARRER, BRUCE DEVENS, STEVEN H. BASS
  • Publication number: 20120128624
    Abstract: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.
    Type: Application
    Filed: December 15, 2011
    Publication date: May 24, 2012
    Inventors: Zailin Yu, Yan Fu
  • Publication number: 20120129766
    Abstract: The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Application
    Filed: November 15, 2011
    Publication date: May 24, 2012
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Brian R. BOETTCHER, Shari L. CAPLAN, Douglas S. DANIELS, Bernhard H. GEIERSTANGER, Norio HAMAMATSU, Stuart LICHT, Andreas LOEW, Stephen Craig WELDON
  • Publication number: 20120122691
    Abstract: Disclosed are composites that comprise regenerated cellulose, a first active substance, a second active substance, and a linker. Methods for preparing the composites that involve the use of ionic liquids are also disclosed. Articles prepared from the disclosed composites and methods of using them are further disclosed.
    Type: Application
    Filed: June 5, 2007
    Publication date: May 17, 2012
    Inventors: Daniel T. Daly, Scott K. Spear, Megan B. Turner, Whitney Lauren Hough, Robin D. Rogers
  • Publication number: 20120121591
    Abstract: Disclosed are compositions of matter having an amino acid sequence of SEQ ID NO:4, or a pharmaceutically acceptable salt thereof, including embodiments comprising a toxin peptide analog related to ShK, HmK, and AETX-K and pharmaceutical compositions or medicaments containing them along with a pharmaceutically acceptable carrier. Some embodiments include a half-life extending moiety. Also disclosed are a method of preventing or mitigating a relapse of a symptom of multiple sclerosis and a method of treating an autoimmune disorder using the compositions.
    Type: Application
    Filed: March 19, 2010
    Publication date: May 17, 2012
    Applicant: Amgen Inc.
    Inventors: John K. Sullivan, Leslie P. Miranda, Colin V. Gegg, Shaw-Fen Sylvia Hu, Edward J. Belouski, Justin K. Murray, Hung Nguyen, Kenneth W. Walker, Taruna Arora, Frederick W. Jacobsen, Yue-Sheng Li, Thomas C. Boone
  • Publication number: 20120123096
    Abstract: Methods are described for improvement of the serum half life of therapeutic nucleic acids by 3? conjugation to useful target proteins, or other large molecules with useful function. In one embodiment, a 3? A, C or G overhang is added to ds-DNA and the primary amines conjugated using biocompatible bifunctional linkers to proteins. The resulting nucleic acid-3? conjugates are serum nuclease-resistant and retained in vivo for long periods without rapid kidney clearance. Further, the choice of conjugate imparts additional functionality to the nucleic acid-3? conjugate.
    Type: Application
    Filed: March 2, 2010
    Publication date: May 17, 2012
    Inventors: John G. Bruno, Judson C. Miner
  • Publication number: 20120115244
    Abstract: Methods of assaying for (i) a pterin by immunoassay employing a pterin as capture agent, (ii) neopterin by chemiluminescent microparticle immunoassay (CMIA) employing an anti-neopterin antibody (Ab) as capture agent, (iii) neopterin by an immunoassay (IA) employing an acridinium (Acr)-labeled anti-neopterin Ab as conjugate, and (iv) neopterin by an IA employing Acr-labeled neopterin as tracer; an Acr-labeled anti-neopterin Ab; a conjugate/complex comprising anti-neopterin Ab and a carrier scaffold; a conjugated pterin; a conjugate comprising an Acr-labeled pterin and a carrier scaffold; an immunogen comprising neopterin and a carrier protein; a conjugate comprising such an immunogen and an Acr compound; an immunogen comprising a carrier protein and a neopterin hapten; a conjugate comprising such an immunogen and an Acr compound; a kit for assaying a pterin comprising a pterin as a capture agent and instructions for IA; and a kit for assaying neopterin comprising an anti-neopterin Ab as a capture agent and ins
    Type: Application
    Filed: November 9, 2010
    Publication date: May 10, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Maciej Adamczyk, R. Jeffrey Brashear, Stephen C. Hsu, Phillip G. Mattingly
  • Publication number: 20120114682
    Abstract: Compositions and methods for targeting substances to fibrinogen, fibrin monomers, or fibrin polymers are provided. These compositions and methods generally involve the use of fibrin knob peptides that bind fibrin(ogen), which can be used to detect fibrin(ogen) and modulate fibrin polymerization and fibrinolysis.
    Type: Application
    Filed: July 9, 2010
    Publication date: May 10, 2012
    Inventor: Thomas Harrison Barker
  • Patent number: 8168756
    Abstract: Methods, compositions and kits are disclosed directed at levetiracetam derivatives, immunogens, signal generating moieties, antibodies that bind levetiracetam and immunoassays for detection of levetiracetam.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: May 1, 2012
    Assignee: ARK Diagnostics, Inc.
    Inventors: Johnny Jose Valdez, Byung Sook Moon, Ki Chung, Alejandro A. Orozco
  • Publication number: 20120101256
    Abstract: The invention relates to a method for providing a multispecific peptide ligand comprising a polypeptide covalently linked to a molecular scaffold at three or more amino acid residues and capable of binding to two or more separate targets, comprising the steps of: (a) providing a first repertoire of polypeptides, each polypeptide comprising two or more reactive groups capable of covalent linkage to a molecular scaffold, and at least one loop which comprises a sequence of two or more amino acids subtended between two of said reactive groups; (b) providing a second repertoire of polypeptides as described in (a); (c) joining at least one loop of one or more members of the first repertoire to at least one loop of one or more members of the second repertoire to form at least one polypeptide comprising two loops, and (d) conjugating the composite polypeptide(s) to a molecular scaffold at at least three amino acid positions.
    Type: Application
    Filed: February 4, 2010
    Publication date: April 26, 2012
    Applicant: Medical Research Council
    Inventors: Gregory Paul Winter, Christian Heinis, Elise Bernard, David Loakes, John Tite, Marina Vaysburd, Daniel Paul Teufel, Lutz Riechmann
  • Publication number: 20120100074
    Abstract: The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the LIGHT polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g. inflammatory bowel disease; Crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and transplantation).
    Type: Application
    Filed: March 22, 2010
    Publication date: April 26, 2012
    Inventors: Rodger Smith, Palanisamy Kanakaraj, Bridget A. Cooksey, Viktor Roschke, Craig Rosen
  • Publication number: 20120094909
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Application
    Filed: April 13, 2011
    Publication date: April 19, 2012
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • Publication number: 20120094316
    Abstract: The invention relates to an immunoassay method and kit for the detection and/or the determination of mephedrone, mephedrone metabolites and related compounds. The invention is underpinned by a novel antibody, derived from a novel immunogen, that is sensitive and binds to mephedrone, mephedrone metabolites and related compounds.
    Type: Application
    Filed: October 18, 2011
    Publication date: April 19, 2012
    Inventors: Robert Ivan McConnell, Elouard Benchikh, Philip Andrew Lowry, Stephen Peter Fitzgerald
  • Patent number: 8158857
    Abstract: The invention is directed to monocot plant seed products comprising human serum albumin, and to methods of making said monocot plant seed products comprising human serum albumin and to therapeutic compositions comprising them.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: April 17, 2012
    Assignee: Ventria Bioscience
    Inventors: Ning Huang, Raymond L. Rodriguez, Frank E. Hagie, David M. Stalker
  • Publication number: 20120088312
    Abstract: Novel conjugates and immunogens derived from vincristine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of vincristine in biological fluids.
    Type: Application
    Filed: October 8, 2010
    Publication date: April 12, 2012
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Daniel J. Cline
  • Publication number: 20120083455
    Abstract: Disclosed are a human serum albumin-siRNA carrier system having siRNA bound to human serum albumin and a user thereof, and especially, human serum albumin-siRNA carrier system, which has a biodegradable covalent bond between human serum albumin polymer and siRNA and is stable in a living body, and a user thereof. The human serum albumin-siRNA carrier system having the biodegradable covalent bond between the human serum albumin and the siRNA exhibits high siRNA delivery efficiency to a target site in the living body. Therefore, the human serum albumin-siRNA carrier system may allow siRNA for therapy to be efficiently delivered to a target site such as cancer tissues in the living body even by being administrated in a relatively low concentration, which may result in a wide use for therapies of various diseases.
    Type: Application
    Filed: September 26, 2011
    Publication date: April 5, 2012
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Kwangmeyung KIM, Ick Chan KWON, Kuiwon CHOI, In Chan YOUN, Myung Sook HUH, Sojin LEE
  • Publication number: 20120077228
    Abstract: Methods for producing modified polypeptides containing amino acid analogues are disclosed. The invention further provides purified dihydrofolate reductase polypeptides, produced by the methods of the invention, in which the methionine residues have been replaced with homoallylglycine, homoproparglycine, norvaline, norleucine, cis-crotylglycine, trans-crotylglycine, 2-aminoheptanoic acid, 2-butynylglycine and allylglycine.
    Type: Application
    Filed: April 28, 2011
    Publication date: March 29, 2012
    Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: David A. Tirrell, Kristi Lynn Kiick
  • Publication number: 20120076728
    Abstract: This invention provides constructs comprising a protein scaffold, wherein the scaffold comprises Domain III, Domain IIIa, or Domain IIIb of human serum albumin or a polypeptide having substantial sequence identity to the Domain III, the Domain IIIa, or the Domain IIIb; and a targeting moiety in covalent linkage to the protein scaffold; and a therapeutic moiety and/or an imaging moiety in covalent linkage to the protein scaffold. The scaffold can be modified to tune the serum pharmacokinetics of the construct. In addition to methods of making the constructs, therapeutic, imaging and diagnostic uses of the constructs are also provided.
    Type: Application
    Filed: April 7, 2010
    Publication date: March 29, 2012
    Applicant: The Regents of the University of California
    Inventors: Anna M. Wu, Vania E. Kenanova, Tove Olafsen
  • Publication number: 20120071632
    Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.
    Type: Application
    Filed: November 23, 2011
    Publication date: March 22, 2012
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Alexander Volkov, Howard Sard, Vishnumurthy Hegde
  • Publication number: 20120059145
    Abstract: An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon. Bioactive peptides thus identified are inherently protease- and peptidase-resistant. Also provided are bioactive peptides stabilized by a stabilizing group at the N-terminus, the C-terminus, or both. The stabilizing group can be a small stable protein, such as the Rop protein, glutathione sulfotransferase, thioredoxin, maltose binding protein, or glutathione reductase, an ?-helical moiety, or one or more proline residues.
    Type: Application
    Filed: August 31, 2011
    Publication date: March 8, 2012
    Applicant: University of Georgia Research Foundation, Inc.
    Inventor: Elliot ALTMAN
  • Publication number: 20120052087
    Abstract: An immunogenic composition comprising a siderophore covalently linked to a pharmaceutically acceptable carrier molecule wherein the antigenicity of the siderophore moiety is sufficient to stimulate an immuno-logic response to the siderophore when the composition is circulating in the bloodstream of a human or non-human animal and vaccine.
    Type: Application
    Filed: April 20, 2010
    Publication date: March 1, 2012
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventor: Raymond J. Bergeron, JR.
  • Publication number: 20120046231
    Abstract: Described herein is a composition and process for synthesizing a human serum albumin (HSA) based plasma replacement composition that includes a polymerized HSA (PolyHSA) that is chemically stabilized by the reduction of Schiff bases. The PolyHSA may have a molecular weight of at least about 100 kDa and may optionally have a cross-linker to HSA molar ratio of at least about 10:1. The PolyHSA composition is useful for restoring a subject's circulatory volume.
    Type: Application
    Filed: August 23, 2011
    Publication date: February 23, 2012
    Inventors: Andre Francis Palmer, Pedro Cabrales
  • Publication number: 20120040378
    Abstract: Carisoprodol is a centrally-acting prescription drug of known abuse. Upon ingestion it is rapidly metabolised to meprobamate, also a prescription drug with abuse potential. Current immunoassays are specific for carisoprodol and therefore have a short window of detection and, furthermore, are ineffective at detecting meprobamate. The current invention, underpinned by an antibody specific for meprobamate, overcomes these deficiencies.
    Type: Application
    Filed: August 9, 2011
    Publication date: February 16, 2012
    Applicant: RANDOX LABORATORIES LIMITED
    Inventors: Elouard Benchikh, Ivan McConnell, Peter Fitzgerald, Philip Lowry
  • Publication number: 20120041178
    Abstract: Provided are a coenzyme Q10 nanoparticle, a method of preparing the same and a composition having the nanoparticle. According to the present invention, Coenzyme Q10 may be dissolved in only a water-miscible organic solvent, and easily made into a nano-sized particle and solubilized under a low energy condition, for example, by simple stirring. The coenzyme Q10 may be dispersion-stabilized by an amino acid or protein. The coenzyme Q10 is formed in a nano-sized particle and solubilized, an absorption rate may be increased and simultaneously deliver the amino acid and protein with the nanoparticle. Thus, the coenzyme Q10 nanoparticle can be effectively used in food, cosmetics and medicine.
    Type: Application
    Filed: April 6, 2010
    Publication date: February 16, 2012
    Applicant: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Bong Hyun Chung, Jung Hyun Han
  • Publication number: 20120041180
    Abstract: Modified human plasma polypeptides or Fc and uses thereof are provided.
    Type: Application
    Filed: July 18, 2011
    Publication date: February 16, 2012
    Applicant: AMBRX, INC.
    Inventors: Joseph SHEFFER, Thea NORMAN, Richard D. DIMARCHI, Anna-Maria A. HAYS PUTNAM, Feng TIAN, Stephanie CHU, Denise KRAWITZ, Ho Sung CHO
  • Patent number: 8114963
    Abstract: Fluorescent dye compounds of formula (I) are disclosed. These compounds are useful as they interact with organic compounds in a manner such that excitation with certain wavelengths of light results in fluorescent emission. Detection and/or monitoring of the fluorescence provides a means for the detection or quantification of organic compounds when bound to these fluorescent dye compounds. Formula (I), wherein: each of R, R? and R? is a hydrogen atom, halogen atom or a straight or branched C1-20 alkyl, alkenyl or alkynl group optionally substituted with one or more halogen, hydroxyl, and/or oxy group; rings A, B and C optionally include one or more double bonds; rings B and C are optionally substituted with one or more halogen atoms.
    Type: Grant
    Filed: December 3, 2007
    Date of Patent: February 14, 2012
    Assignee: Flurotechnics Pty Limited
    Inventors: Philip John Livingston Bell, Peter Karuso
  • Publication number: 20120021437
    Abstract: Tetranor-PGDM/tetranor-PGJM-specific antibodies, immunogens used to generate them, the processes of their manufacture, and their uses in assay kits for detecting and quantifying tetranor-PGDM and tetranor-PGJM in biological fluids for determining biosynthesis of PGD2 in a subject or patient.
    Type: Application
    Filed: June 14, 2011
    Publication date: January 26, 2012
    Applicant: Cayman Chemical Company, Incorporated
    Inventors: Jeffrey K. Johnson, Kirk M. Maxey, Daniel J. Tew, Andriy M. Kornilov